Market Cap£584.7m

Last Close 1190p

Ergomed is a global full-service CRO business with a core focus on the United States and the EU. It provides Phase I–III clinical services in addition to post-marketing pharmacovigilance (Phase IV) services and is predominantly focused on oncology, orphan drugs, rare diseases and pharmacovigilance.

More Ergomed content >

Investment summary

Ergomed proved to be a resilient business, which we attribute to a diversified and well-balanced pharma services offering (contract research outsourcing (CRO) and pharmacovigilance). Furthermore, Ergomed’s H121 results highlight that operational momentum continues to be strong following its stellar performance in FY20. Total revenues increased to £56.0m, up 48.1% on constant exchange rate basis (CER; 38.8% reported) y-o-y. Adjusted EBITDA increased to £12.1m, up 33% from H120 (£9.1m), while adjusted EPS was 16.8p, up 48.7% from H120 (11.3p). H121 results were substantially affected by FX headwinds, reflecting the increasing US$ contribution (now c 63% of the mix) after the US-based MedSource acquisition in December 2020. Growth was driven by a solid order book (£227.8m, up 51% y-o-y) and healthy new business wins in H121 (£90.8m, up 50.8% y-o-y). This provides high visibility for H221 and into 2022.

Y/E Dec
Revenue (£m)
PBT (£m)
EPS (p)
P/E (x)
P/CF (x)
2019A 68.3 12.5 8.6 19.8 60.1 47.0
2020A 86.4 19.4 14.4 23.7 50.2 31.9
2021E 119.6 24.0 20.2 34.1 34.9 36.4
2022E 136.9 27.9 24.1 40.5 29.4 27.7
Industry outlook

Innovation in healthcare is driving sales and growth in the number of clinical trials being initiated, as pharmaceutical and biotechnology companies continue to invest substantially. Tight operational control and execution will enable Ergomed to drive market share in high-growth orphan drug trials as well as in larger indications.

Last updated on 20/01/2022
Content on Ergomed
Ergomed – US is now the biggest market in the mix
Healthcare | Update | 4 October 2021
Ergomed – Momentum continues with EBITDA upgrades
Healthcare | Update | 11 August 2021
View more
Register to receive research on Ergomed as it is published
Share price graph
Balance sheet
Forecast net cash (£m) 31.4
Forecast gearing ratio (%) N/A
Price performance
Actual (15.3) (19.3) 13.3
Relative* (19.0) (22.3) 1.2
52-week high/low 1540.0p/980.0p
*% relative to local index
Key management
Richard Barfield CFO
Dr Miroslav Reljanović Executive chairman